Prof. John Kelly (The Alfred Hospital, Australia) stated that surgery for melanoma has changed [1]. Sentinel lymph node biopsy (SLNB) is still indicated in all melanomas equal to or greater than 1 mm. However, its predictive value is limited given that 62% and 48% of patients with intermediate or thick melanomas, respectively, who have positive results will still be alive at 10 years. On the other hand, 35% of patients with thick tumours will die within 10 years after a negative result [2].
Surgery remains the standard of care for clinically evident stage III disease, also after neoadjuvant treatment. In stage IV, surgery is only indicated in easily resectable or imminently threatening meSkin lanoma, because stage IV is now the mainstay of systemic therapy. Surgery is used initially for brain metastases. In addition, it can be a valuable option for patients progressing during immune or targeted therapy.
- Kelly J. 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Grob JJ. Melanoma Letter 2015.
Posted on
Previous Article
« What the future of keloid treatment could hold Next Article
Novel selective IL-23 blocker highly effective over 2 years »
« What the future of keloid treatment could hold Next Article
Novel selective IL-23 blocker highly effective over 2 years »
Table of Contents: WCD 2019
Featured articles
Letter from the Editor
Insights into pathogenesis of AD define novel therapeutic targets
Treating Psoriasis in 2019
Choosing the right biologic in psoriasis
Registries – an important research tool in biologics
Atopic Dermatitis – What is New
Insights into pathogenesis of AD define novel therapeutic targets
Combinations are hot in AD treatment
Dermal Reactions to Systemic Drugs
Cutaneous adverse events due to EGFR inhibitors
Management strategies for drug-induced mucositis
Skin toxicity of immune checkpoint inhibitors
Lupus Erythematosus Today
New targets and biologics for cutaneous lupus erythematosus
Novel lupus classification will aid future research
Hidradenitis Suppurativa
Various guidelines with much overlap
Antibiotics in hidradenitis suppurativa
Biologicals beyond TNF blockade
Small Molecules – What to Expect
Novel treatment options for many dermatologic indications
Long awaited oral therapy for moderate-to-severe AD
Novel treatment options in alopecia areata and vitiligo
Optimising the Management of Keloids
Keloids: a faulty switch in wound healing?
What the future of keloid treatment could hold
Malignant Melanoma – Advances in Management
Will malignant melanoma become a curable disease?
Best of the Posters
Related Articles
June 21, 2019
Favourable safety profile of long-term use of ixekizumab
May 9, 2019
IBD risk of treatment with IL-17 antagonists
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy